NICE recommends Eladynos for treating osteoporosis

UK health technology assessor the National Institute for Health and Care Excellence (NICE) has recommended Eladynos (abaloparatide), from UK-based women’s health care specialist Theramex, for the treatment of osteoporosis in postmenopausal women at increased risk of fracture, through the National Health Service (NHS).

In England and Wales, it is estimated that more than two million women have osteoporosis. Theramex acquired rights to Eladynos las year from Radius Health on an exclusive basis in the European Economic Area, the UK, Australia and Brazil.

Now available to >4,000 eligible postmenopausal women in England and Wales, Eladynos can be injected at home, once a day, allowing for treatment flexibility.